Clinical Trials And ApprovalsMino-Lok has the potential to salvage the catheter with a 100% salvage rate in Phase 2b.
Market PotentialThere is potential for Lymphir to become a significant revenue driver within cutaneous T cell lymphoma.
Regulatory ProgressThe FDA provided clear, constructive, and actionable guidance for a future New Drug Application submission for Mino-Lok, supporting its pathway to regulatory approval.